Cyteir Therapeutics, Inc. (CYT)
Cyteir Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing the next-generation of precision oncology medicines that inhibit deoxyribonucleic acid, or DNA, damage repair and cause cancer cell death through a therapeutic strategy known as synthetic lethality.
Synthetic lethality represents a clinically validated approach to drug development and arises when there is a deficiency in either of two conditions that are tolerable alone in cells but lethal together.
Our lead program, CYT-0851, is in a phase 1/2 trial in adult patients with hematologic malignancies and solid tumors. If warranted by the phase 1/2 data, and subject to FDA agreement, we could initiate a potentially registrational trial in 2022 for the treatment of relapsed and/or refractory lymphoma and/or solid tumors.
We also plan to develop CYT-0851 in additional tumor settings as both a monotherapy and in combination with approved cancer therapeutics and plan to initiate dosing in a phase 1/2 trial that explores tolerability and preliminary activity of combinations with standard-of-care therapies in the second half of 2021.
|IPO Date||Jun 18, 2021|
|CEO||Markus Renschler, M.D.|
128 Spring St, Building A, Suite 510
Lexington, MA 02421
|Phone||857 285 4140|
|Fiscal Year||January - December|
|Reporting Currency||US Dollars|
|Joseph S. Zakrzewski||Independent Investor and Chairman|
|Dr. Markus F. Renschler M.D.||President, Chief Executive Officer and Director|
|Timothy Romberger||Independent Director|
|Dr. Paul Secrist Ph.D.||Chief Scientific Officer|
|Andrew W. Gengos||Chief Business Officer|
|Dr. Kevin Mills||Co-Founder|
|David G. Gaiero||Vice President of Finance|
|Lisa A. Hayes||Vice President of Investor Relations and Corporate Communications|
|Gale Cohen||Vice President of Human Resources|
|Dr. Tom O'Shea Ph.D.||Senior Vice President of Clinical Pharmacology and Preclinical Development|